Introduction Session 10: Canada and U.S. Approaches to Cross-Border Sales of Pharmaceuticals

Matthew Schaefer

Follow this and additional works at: http://scholarlycommons.law.case.edu/cuslj
Part of the Transnational Law Commons

Recommended Citation
Available at: http://scholarlycommons.law.case.edu/cuslj/vol31/iss/43

This Speech is brought to you for free and open access by the Student Journals at Case Western Reserve University School of Law Scholarly Commons. It has been accepted for inclusion in Canada-United States Law Journal by an authorized administrator of Case Western Reserve University School of Law Scholarly Commons.
SESSION 10: CANADA AND U.S. APPROACHES TO CROSS-BORDER SALES OF PHARMACEUTICALS.

INTRODUCTION

Matthew Schaefer

Well, let’s go ahead and begin. This panel will focus on cross-border sales of pharmaceuticals, and we had a session with the press last night, and this is probably an issue between the U.S. and Canada that gets probably as much press as any other issue, and we are very fortunate to have two excellent speakers to lead us through the issue.

To my right is Professor Sara Rosenbaum. She is the Harold and Jane Hirsh Professor of Health Law and Policy, and Chair of the Department of Health Policy at the George Washington University School of Public Health and Health Services. She also holds appointments with the Schools of Medicine and Health Sciences, and Law. Professor Rosenbaum worked for the White House Domestic Policy Council during the 1993-94 time period, and directed the drafting of the Health Security Act for President Clinton at that time.

To my left is Jennifer Orange, who practices civil litigation for Torys, LLP in Toronto, and she has also recently served a stint working for Mary Robinson’s new nonprofit organization, the Ethical Globalization Initiative.

We will start with Sara, who will tell us how we got into some of these problems, and then turn to Jennifer for some of the Canadian perspectives.